Literature DB >> 26191272

Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.

Lei Liu1, Weiqing Qu1, Zhaokun Zhong1.   

Abstract

OBJECTIVE: We aimed to explore what impact miR-503 has on the prognosis of patients with non-small cell lung cancer (NSCLC).
METHODS: Cancer and matched non-malignant lung tissue specimens were collected from 109 patients who underwent surgery in Tanisha Hospital from Jun 2006 to July 2013. Overall survival (OS) curves were analyzed using the Lapland-Meier method, and the differences were examined using log-rank tests. Cox proportional- hazards regression analysis was applied in order to estimate univariate and multivariate hazard ratios for OS.
RESULTS: The relative expression of miR-503 in NSCLC tissues (0.366±0.130) was significantly lower than that in matched noncancerous lung tissues (1.667±1.047, P<0.01). Statistically significant association was observed between miR-503 expression and lymphatic invasion (P=0.005), distant metastasis (P=0.002), TNM stage (P=0.008), and tumor grade (P=0.043). Lapland Meier analysis clearly illustrated that the patients with the lower expression of miR-503 had a worse outcome compared to patients with higher miR-503 expression (P=0.004). Furthermore, multivariate analysis revealed that miR-503 expression level was an independent prognostic factor for overall survival (HR=3.992, 95% CI: 2.276-9.872; P=0.018) in NSCLC.
CONCLUSION: In patients with NSCLC, low miR-503 expression is an independent prognostic factor.

Entities:  

Keywords:  NSCLC; biomarker; miR-503; micro RNA; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26191272      PMCID: PMC4503143     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

Review 1.  A computational view of microRNAs and their targets.

Authors:  James R Brown; Philippe Sanseau
Journal:  Drug Discov Today       Date:  2005-04-15       Impact factor: 7.851

Review 2.  miRNAs, cancer, and stem cell division.

Authors:  Carlo M Croce; George A Calin
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

Review 3.  Genomics of microRNA.

Authors:  V Narry Kim; Jin-Wu Nam
Journal:  Trends Genet       Date:  2006-01-30       Impact factor: 11.639

4.  Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis.

Authors:  Jian-Jun Zhao; Juhua Yang; Jianhong Lin; Nan Yao; Yihua Zhu; Jianlong Zheng; Jianhua Xu; Jin Q Cheng; Jian-Yin Lin; Xu Ma
Journal:  Childs Nerv Syst       Date:  2008-09-26       Impact factor: 1.475

Review 5.  miRNAs: Little known mediators of oncogenesis.

Authors:  Andrei L Gartel; Eugene S Kandel
Journal:  Semin Cancer Biol       Date:  2008-01-16       Impact factor: 15.707

Review 6.  Regulatory mechanisms of microRNAs involvement in cancer.

Authors:  Muller Fabbri; Mircea Ivan; Amelia Cimmino; Massimo Negrini; George A Calin
Journal:  Expert Opin Biol Ther       Date:  2007-07       Impact factor: 4.388

7.  Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.

Authors:  Zsófia Tömböl; Peter M Szabó; Viktor Molnár; Zoltán Wiener; Gergely Tölgyesi; János Horányi; Peter Riesz; Peter Reismann; Attila Patócs; István Likó; Rolf-Christian Gaillard; András Falus; Károly Rácz; Peter Igaz
Journal:  Endocr Relat Cancer       Date:  2009-06-22       Impact factor: 5.678

Review 8.  MicroRNA-143 and -145 in colon cancer.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  DNA Cell Biol       Date:  2007-05       Impact factor: 3.311

Review 9.  Post-transcriptional gene regulation: from genome-wide studies to principles.

Authors:  R E Halbeisen; A Galgano; T Scherrer; A P Gerber
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

10.  Systematic validation of predicted microRNAs for cyclin D1.

Authors:  Qiong Jiang; Ming-Guang Feng; Yin-Yuan Mo
Journal:  BMC Cancer       Date:  2009-06-18       Impact factor: 4.430

View more
  11 in total

1.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

2.  MicroRNA-503 suppresses cell proliferation and invasion in osteosarcoma via targeting insulin-like growth factor 1 receptor.

Authors:  Zili Wang; Chenhuang Zheng; Kunqi Jiang; Jinshen He; Xu Cao; Song Wu
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

3.  TGF-â1-induced miR-503 controls cell growth and apoptosis by targeting PDCD4 in glioblastoma cells.

Authors:  Pin Guo; Yanan Yu; Huanting Li; Daoxiang Zhang; Anjing Gong; Shifang Li; Wei Liu; Lei Cheng; Yongming Qiu; Weicheng Yao; Luo Li; Yugong Feng
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

4.  MicroRNA‑503 serves an oncogenic role in laryngeal squamous cell carcinoma via targeting programmed cell death protein 4.

Authors:  Yu Shuang; Xuan Zhou; Chao Li; Yongwang Huang; Lun Zhang
Journal:  Mol Med Rep       Date:  2017-08-17       Impact factor: 2.952

5.  Overexpression of miR-758 inhibited proliferation, migration, invasion, and promoted apoptosis of non-small cell lung cancer cells by negatively regulating HMGB.

Authors:  Guo-Hua Zhou; Yi-Yu Lu; Jing-Lian Xie; Zi-Kun Gao; Xiao-Bo Wu; Wei-Shen Yao; Wei-Guang Gu
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

6.  MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway.

Authors:  Wenjing Li; Jun Li; Hong Mu; Meiqi Guo; Haixia Deng
Journal:  Cancer Cell Int       Date:  2019-06-14       Impact factor: 5.722

7.  MicroRNA-503 Inhibits Non-Small Cell Lung Cancer Progression By Targeting PDK1/PI3K/AKT Pathway.

Authors:  Yingying Wei; Yuanfan Liao; Yu Deng; Yukun Zu; Bo Zhao; Fan Li
Journal:  Onco Targets Ther       Date:  2019-10-31       Impact factor: 4.147

8.  MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor.

Authors:  Yao Xiao; Qinggang Tian; Jiantai He; Ming Huang; Chao Yang; Liansheng Gong
Journal:  Onco Targets Ther       Date:  2016-06-15       Impact factor: 4.147

Review 9.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

10.  MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1.

Authors:  Weiwen Yan; Qiuyun Wu; Wenxi Yao; Yan Li; Yi Liu; Jiali Yuan; Ruhui Han; Jingjin Yang; Xiaoming Ji; Chunhui Ni
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.